Lung Injury Induced by Antitumor Drugs: Prevalence, Certain Drugs and Their Mechanisms of Action. Part 2
https://doi.org/10.21292/2075-1230-2021-99-8-54-60
Abstract
The article analyzes 49 publications on adverse drug reactions occurring during therapy with antitumor drugs. It presents data on pneumotoxicity and its clinical manifestations for such anticancer drugs as bleomycin, busulfan, cyclophosphamide, chlorambucil, methotrexate, nitrosourea derivatives, and taxanes, while the mechanisms of lung injury are not entirely clear and require further research. The prevention of drug-induced lung injury requires raising awareness among practicing physicians of different specialties, primarily general practitioners, rheumatologists, clinical immunologists, pulmonologists, phthisiologists, and oncologists due to non-specific manifestations of drug-induced lung injury and the use of antitumor drugs for other diseases apart from cancer.
About the Authors
N. V. Orlova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Orlova Natalia V., Doctor of Medical Sciences, Professor. 1, Ostrovityanova St., Moscow, 117997.
Phone: +7 (495) 674-48-68
O. D. Ostroumova
Russian Medical Academy of On-going Professional Education
Russian Federation
Russian Federation
Ostoumova Olga D., Doctor o f Medical Sciences, Professor, Head of Department of Therapy and Polymorbid Pathology
2/1, Build. 1. Barrikadnaya St., Moscow, 125993
Phone: +7 (495) 945-11-28.
E. V. Shikh
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Shikh Evgeniya V., Doctor of Medical Sciences, Professor, Head of Department of Clinical Pharmacology and Propedeutics o f Internal Diseases, Director of Professional Education Institut
8, Bd. 2, Trubetskaya St., Moscow, 119991
S. V. Smerdin
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Smerdin Sergey V., Doctor o f Medical Sciences, Professor, Chief Physician
1b, Village o f Sukmanikha, Schelkovsky Raion, Moscow Region, 141132
Phone: +7 (499) 978-02-43.
E. V. Rebrova
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Rebrova Ekaterina V., Candidate of Medical Sciences, Associate Professor of Department of Clinical Pharmacology and Propedeutics of Internal Diseases
Phone: +7 (495) 609-14-00.
8, Bd. 2, Trubetskaya St., Moscow, 119991
V. А. Dyo
Russian Medical Academy of On-going Professional Education
Russian Federation
Russian Federation
Dyo Valeria A., Resident of Department o f Therapy and Polymorbid Pathology.
2/1, Build. 1. Barrikadnaya St., Moscow, 125993
Phone: +7 (495) 945-11-28
References
1. Ahya V. N. Noninfectious Acute lung injury syndromes early after hematopoietic stem cell transplantation. Clin. Chest Med., 2017, no. 38 (4), pp. 595.
2. Alessandrino E. P., Bernasconi P., Colombo A. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow transplant., 2000, no. 25, pp. 309.
3. Becker C. D., Gil J., Padilla M. L. Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity? Mod. Pathol., 2008, no. 21, pp. 784.
4. Bertrand M., Wemeau-Stervinou L., Gauthier S. New toxicity of fotemustine: diffuse interstitial lung disease. Ann. Dermatol. Venereol. 2012, no. 139, pp. 277.
5. Beynat-Mouterde C., Beltramo G., Lezmi G. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J., 2014, no. 44, pp. 523.
6. Bielopolski D., Evron E., Moreh-Rahav O. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J. Chemother., 2017, no. 29, pp. 113.
7. Bonniaud P., Georges M., Favrolt N., Camus P. Drug-induced interstitial lung diseases. Rev. Prat., 2014, no. 64, pp. 951.
8. Bredeson C., LeRademacher J., Kato K. et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood, 2013, no. 122, pp. 3871.
9. Brockstein B. E., Smiley C., Al-Sadir J., Williams S. F. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant., 2000, no. 25, pp. 885.
10. Camus P. Interstitial lung disease from drugs, biologics, and radiation. Interstitial Lung Disease, 5th. Eds.: Schwarz M., King T.E.Jr. People’s Medical Publishing House-USA, Shelton CT. 2011, 637 p.
11. Camus P. The drug-induced respiratory disease website. www.pneumotox.com (Accessed on June 23, 2017).
12. Camus P., von der Thusen J., Hansell D.M., Colby T.V. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? Eur. Respir. J., 2014, no. 44, pp. 289.
13. Cao T. M., Negrin R.S., Stockerl-Goldstein K.E., Johnston L.J., Shizuru J.A., Taylor T.L., Rizk N.W., Wong R.M., Blume K.G., Hu W.W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2000, no. 6 (4), pp. 387-394.
14. Catovsky D., Richards S., Matutes E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 2007, no. 370, pp. 230.
15. Copelan E. A., Hamilton B. K., Avalos B. et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood, 2013, no. 122, pp. 3863.
16. Dhokarh R., Li G., Schmickl C. N., Kashyap R., Assudani J., Limper A.H., Gajic O. Drug-associated acute lung injury: a population-based cohort study. Chest, 2012, pp. 845.
17. Dormann H., Muth-Selbach U., Krebs S., Criegee-Rieck M., Tegeder I., Schneider H. T., Hahn E. G., Levy M., Brune K., Geisslinger G. Incidence and costs of adverse drug reactions during hospitalization. Drug Safety, 2000, no. 22 (2), pp. 161-168.
18. Fernandez H. F., Tran H. T., Albrecht F. et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant diseaseundergoing stem cell transplantation. Biol. Blood Marrow Transplant., 2002, no. 8, pp. 486.
19. Frankel S. K., Cool C. D., Lynch D. A., Brown K. K. Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest, 2004, no. 126, 2007.
20. Fujimoto D., Kato R., Morimoto T., Shimizu R., Sato Yu., Kogo M., Ito J., Teraoka Sh., Nagata K., Nakagawa A., Otsuka K., Tomii K. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS One, 2016, pp. 11.
21. Grove M. L., Hassell A. B., Hay E. M., Shadforth M. F. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM, 2001, no. 94, pp. 309.
22. Hanel M., Kroger N., Sonnenberg S., et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann. Hematol., 2002, no. 81, pp. 96.
23. Ho V. T., Weller E., Lee S.J., Alyea E. P., Antin J.H., Soiffer R. J. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 2001, no. 7 (4), pp. 223-229.
24. Imokawa S., Colby T.V., Leslie K. O., Helmers R. A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur.Respir. J., 2000, no. 15, pp. 373-381.
25. Kalambokis G., Stefanou D., Arkoumani E., Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia. Eur. J. Haematol., 2004, no. 73, pp. 139.
26. Kim H.Y., Hwang J. H., Chang Y. W., Moon J. Y. Pulmonary Complications of Antineoplastic Agents: Era of Targeted Therapy. ECR, 2013, no. 1230, pp. 1-30.
27. Kinder A. J., Hassell A. B., Brand J., Brownfield A., Grove M., Shadforth M.F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford), 2005, no. 44, pp. 61-66.
28. Kreisman H., Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol., 1992, no. 19, pp. 20.
29. Kubo K., Azuma A., Kanazawa M., Kameda H., Kusumoto M., Genma A., Saijo Y., Sakai F., Sugiyama Y., Tatsumi K., Dohi M., Tokuda H., Hashimoto S., Hattori N., Hanaoka M., Fukuda Y. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir. Invest., 2013, no. 51, pp. 260-277.
30. Le Guillou F., Dominique S., Dubruille V. et al. Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration. Rev. Mai. Respir., 2003, no. 20, pp. 273.
31. Lee M. Y., Yoon S. Y., Kim K. H., Lee N., Kim H. Y., Hwang J. H., Jong-Ho Won J.H. Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience. Korean J. Intern. Med., 2021, pp. 1-10.
32. Meadors M., Floyd J., Perry M. C. Pulmonary toxicity of chemotherapy. Semin Oncol., 2006, no. 33, pp. 98.
33. Orchard P. J., Fasth A. L., Le Rademacher J. et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood, 2015, no. 126, pp. 270.
34. O’Sullivan J. M., Huddart R. A., Norman A. R., Nicholls J., Dearnaley D. P., Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncology, 2003, vol. 14, no. 1, pp. 91-96.
35. Ozkan М., Dweik R.A. Drug-induced lung disease. Cleveland Clin. J. Med., 2001, no. 68 (9), pp. 782-795.
36. Panoskaltsis-Mortari A., Griese M., Madtes D. K. et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am. J. Respir. Crit. Care Med., 2011, no. 183, pp. 1262.
37. Peters C., Schrappe M., von Stackelberg A. et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J. Clin. Oncol., 2015, no. 33, pp. 1265.
38. Remesh A. Toxicities of anticancer drugs and its management. Int. J. Basic Clin. Pharmacol., 2012, no. 1, pp. 2-12.
39. Robert C., Ribas A., Wolchok J. D., Hodi F. S., Hamid O., Kefford R., Weber J. S., Joshua A. M., Hwu W-J., Gangadhar T. C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus Ch., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus Sc. W., Kang S. P., Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, no. 9948, pp. 1109-1117.
40. Rosenow 3rd E. C. Drug-induced pulmonary disease. Dis. Mon., 1994, no. 40, pp. 253-310.
41. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum Dis., 2009, no. 68, pp. 1100.
42. Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford), 2006, no. 45, pp. 787.
43. Segura A., Yuste A., Cercos A. et al. Pulm onary fibrosis induced by cyclophosphamide. Ann. Pharmacother., 2001, no. 35, pp. 894.
44. Shafqat H., Olszewski A. J. Chlorambucil-induced acute interstitial pneumonitis. Case Rep. Hematol., 2014, е575417.
45. Sleijfer S. Bleomycin-induced pneumonitis. Chest, 2001, no. 120, pp. 617.
46. Ulrickson M., Aldridge J., Kim H. T. et al. Busulfan and yclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol. Blood Marrow Transplant., 2009, no. 15, pp. 1447.
47. Wei-I L., Hissaria P. Drug-Induced Interstitial Lung Disease. Indian J. Rheumatology, 2021, no. 21, pp. 19-26.
48. Zarogoulidis P, Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E. P., Karamanos N., Zarogoulidis K. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine. Int. J. Nanomed, 2012, no. 7, pp. 1551-1572.
49. Zucca E., Conconi A., Laszlo D. et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J. Clin. Oncol., 2013, no. 31, pp. 565.
Review
For citations:
Orlova N.V., Ostroumova O.D., Shikh E.V., Smerdin S.V., Rebrova E.V., Dyo V.А. Lung Injury Induced by Antitumor Drugs: Prevalence, Certain Drugs and Their Mechanisms of Action. Part 2. Tuberculosis and Lung Diseases. 2021;99(8):54-60. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-8-54-60
Views:
643
Email this article 